Management of metastatic castration-resistant prostate cancer after first-line docetaxel-Reference-Cited by-同舟云学术

Management of metastatic castration-resistant prostate cancer after first-line docetaxel

Published:2011-09 Issue:14 Volume:47 Page:2133-2142
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Harrington J.A.,Jones R.J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference73 articles.

1. Screening for prostate cancer: an update;Bryant;Eur Urol,2008

2. Estimates of cancer incidence and mortality in Europe in 2008;Ferlay;Eur J Cancer,2010

3. Bray F. The burden of cancer in Europe. In: Coleman MP, Alexe D-M, Albrecht T, McKee M, editors. Responding to the challenge of cancer in Europe. Institute of Public Health of the Republic of Slovenia; 2008: pp. 7–39.

4. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets;Chi;Eur Urol,2009

5. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration‐resistant prostate cancer;The Prostate;2021-10-21

2. Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis;Molecules;2021-01-13

3. Impact of taxanes on androgen receptor signaling;Asian Journal of Andrology;2019

4. Fighting tubulin-targeting anticancer drug toxicity and resistance;Endocrine-Related Cancer;2017-09

5. Pathophysiology of Castration-Resistant Prostate Cancer;Managing Metastatic Prostate Cancer In Your Urological Oncology Practice;2016